Related Experiment Video
Updated: Jul 19, 2026
11:34
Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
Published on: April 29, 2017
Radiolabeled L-lysine for tumor imaging
Alper O Karacalioglu1, David J Yang, Ali Azhdarinia
1Department of Experimental Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 57, Houston, TX 77030, USA.
Academic Radiology
|October 31, 2006
Summary
This study successfully developed and validated technetium-99m-labeled DMSA-l-lysine for tumor imaging. The radiopharmaceutical demonstrated efficient labeling, high purity, and promising in vivo and in vitro tumor uptake characteristics.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Chemistry
- Oncology
Background:
- L-lysine is a versatile amino acid with potential for targeted drug delivery.
- Developing novel radiopharmaceuticals is crucial for improving cancer diagnostics.
- Technetium-99m (99mTc) is a widely used radioisotope for medical imaging due to its favorable properties.
Purpose of the Study:
- To synthesize and radiolabel L-lysine with 99mTc using 2,3-dimercapto-succinic acid (DMSA).
- To evaluate the in vitro and in vivo tumor imaging feasibility of 99mTc-DMSA-l-lysine.
- To determine the subcellular biodistribution of the developed radiopharmaceutical.
Main Methods:
- Chemical synthesis of DMSA-l-lysine and subsequent labeling with 99mTc.
- Characterization using NMR and mass spectrometry; purity assessed by TLC and paper chromatography.
- In vitro studies included cellular uptake and competition assays in rat breast cancer cells (13762).
- In vivo studies involved planar imaging and biodistribution in Fischer 344 rats; dosimetry calculations were performed.
Main Results:
- Radiochemical purity of 99mTc-DMSA-l-lysine exceeded 95%.
- Significant in vitro cellular uptake was observed, decreasing with competition.
- The radiopharmaceutical showed accumulation in both nucleus and cytoplasm, increasing over time.
- In vivo studies demonstrated favorable tumor-to-background ratios (up to 6.87 at 2 hours) and acceptable radiation dosimetry for organs.
Conclusions:
- DMSA-l-lysine kits offer an easy, efficient, and cost-effective method for 99mTc radiolabeling.
- In vitro and in vivo studies confirm the pharmacokinetic distribution and imaging potential of 99mTc-DMSA-l-lysine for tumor detection.
